Fig. 5.

PAK1 overexpression reverses the anti-neoplastic effects of MIA-602. (A) KATO-III and SGC-7901 cells were transiently transfected with PAK1-overexpressing plasmid or control vector and were subjected to Western blotting for the indicated antigens. β-Actin was used as an internal control. (B) The viability of PAK1-overexpressing cells that were treated with MIA-602 (1 μM) or vehicle for 48 h was assessed by MTT assay. Error bars indicate SEM. *P < 0.05, **P < 0.01, ***P < 0.001 by one-way ANOVA with post hoc intergroup comparisons; n = 3 in each group.